ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray

When Novartis won FDA approval for its breast cancer drug Piqray in HR-positive/HER2-negative patients with PIK3CA mutations last year, early survival data was impressive: Combining the drug with AstraZeneca’s Faslodex nearly doubled the time to disease progression or death to 11 months over Faslodex alone.